1. Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors

    Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to the Company's Board of Directors...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Partner Publications, Question of The Week, Sponsored Content
  2. Topics Mentioned